[Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea]

Ko MJ, Kim Y, Hong SR, Lee JK, Shim J, Kim J, Choi SM, Lee YJ, Koh JS, Kim DY, Sung SH, Park H, Yoo CW, Lee KH, Lee JW, Chae SW
Record ID 32014001103
Korean
Authors' recomendations: To estimate the accuracy of cervical cancer screening methods in Korea, we performed a meta-analysis among asymptomatic women for cervical cancer screening. The estimated sensitivity and specificity for pap smear were 0.84(95% CI:0.75-0.90) and 0.78 (95% CI:0.65-0.87) respectively, and the variability of diagnostic accuracy among studies using pap smear was relatively low compared with that of HPV testing. The cost-effectiveness analysis of the selected cervical cancer screening strategies was carried out with consideration of various screening intervals (1, 2, 3, or 5 year), starting ages (20 or 30 years), and discontinuation ages (lifetime, 79 years) for each screening method. The cost-effectiveness analysis of the selected cervical cancer screening strategies revealed that pap smear testing at 1-year intervals (aged 30 to life-time) was the most cost-effective strategy with an incremental cost-utility ratio (ICUR) below KRW 30,000,000won/QALY. For the estimation of representative diagnostic accuracy and economic evaluation of cervical screening methods, more studies are strongly warranted in various medical institutions targeting-asymptomatic women for cervical cancer screening.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
MeSH Terms
  • Uterine Cervical Neoplasms
  • DNA Probes, HPV
  • Mass Screening
  • Cytological Techniques
Contact
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: int@neca.re.kr
Contact Email: int@neca.re.kr
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.